Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Pedro Luiz Serrano Usón

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6122-1374; OpenAlex author ID A5052890292, A5112451322. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 4 papers

Papers 21

  1. Periostin-positive stellate cells associated with perineural invasion in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.mce.2025.112678↗
  2. Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. Last author DOI 10.1038/s41598-026-40757-3↗
  3. Irreversible electroporation combined with immunotherapy versus irreversible electroporation alone for locally advanced pancreatic cancer: a systematic review … Co-author DOI 10.31744/einstein_journal/2026rw1656↗
  4. Social Progress Index as a Determinant of Healthcare Access and Treatment in Pancreatic Cancer. Co-author DOI 10.3390/curroncol33060346↗
  5. Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten? Co-author DOI 10.5306/wjco.v16.i9.108955↗
  6. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer. First author DOI 10.1080/14656566.2024.2304125↗
  7. Concomitant or antecedent intraductal papillary mucinous neoplasm is not a prognostic factor in resected pancreatic cancer. Co-author DOI 10.21037/jgo-24-157↗
  8. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials. Co-author DOI 10.1016/j.esmoop.2022.100771↗
  9. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis. Co-author DOI 10.1038/s41598-022-17743-6↗
  10. Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib. Co-author DOI 10.3390/biomedicines10112705↗
  11. Increasing Stress to Induce Apoptosis in Pancreatic Cancer via the Unfolded Protein Response (UPR). Co-author DOI 10.3390/ijms24010577↗
  12. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13717↗
  13. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Co-author DOI 10.14309/ctg.0000000000000414↗
  14. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. First author DOI 10.3389/fonc.2021.794009↗
  15. The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies. Co-author DOI 10.1371/journal.pone.0230060↗
  16. BODY COMPOSITION IMPACT ON SURVIVAL AND TOXICITY OF TREATMENT IN PANCREATIC CANCER: CROSS-SECTIONAL PILOT STUDY. Co-author DOI 10.1590/s0004-2803.202000000-52↗
  17. Establishing recurrence indicators and stratifying pancreatic ductal adenocarcinoma based on routine laboratory exams. Is it time to incorporate these paramete… Co-author PMID 32277666↗
  18. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. Co-author DOI 10.1007/s12029-017-0007-x↗
  19. Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1016/j.clcc.2018.03.007↗
  20. Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered. Co-author DOI 10.1590/s1679-45082015ao3303↗
  21. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. Co-author DOI 10.3978/j.issn.2078-6891.2015.041↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitesh J. Borad · 7 shared papers, 2021–2026 · strength 1.27
  2. Fernando Moura · 5 shared papers, 2018–2026 · strength 0.93
  3. Gehan Botrus · 5 shared papers, 2021–2022 · strength 0.69
  4. Mohamad Bassam Sonbol · 4 shared papers, 2021–2026 · strength 0.62
  5. Tanios Bekaii‐Saab · 4 shared papers, 2021–2026 · strength 0.62
  6. Francisco Tustumi · 2 shared papers, 2024–2026 · strength 0.46
  7. Diogo Diniz Gomes Bugano · 3 shared papers, 2018–2024 · strength 0.43
  8. Raphael L. C. Araújo · 1 shared paper, 2025 · strength 0.42
  9. Kunal C. Kadakia · 1 shared paper, 2025 · strength 0.42
  10. Daniel H. Ahn · 3 shared papers, 2021 · strength 0.32
  11. Kathlen Oliveira Martins Tiede · 1 shared paper, 2026 · strength 0.30
  12. Himil J Mahadevia · 1 shared paper, 2024 · strength 0.28
  13. Jing Wang · 1 shared paper, 2024 · strength 0.28
  14. Hani M. Babiker · 1 shared paper, 2024 · strength 0.28
  15. Felipe B. Maegawa · 1 shared paper, 2026 · strength 0.28
  16. Nelson Wolosker · 1 shared paper, 2026 · strength 0.28
  17. Lucas Cata Preta Stolzemburg · 1 shared paper, 2026 · strength 0.28
  18. Stephan Altmayer · 1 shared paper, 2026 · strength 0.27
  19. Rodrigo Gobbo Garcia · 1 shared paper, 2026 · strength 0.27
  20. Miriana Mariussi · 1 shared paper, 2026 · strength 0.27
  21. Helder Imoto Nakaya · 1 shared paper, 2026 · strength 0.24
  22. Carlos Alberto de Carvalho Fraga · 1 shared paper, 2026 · strength 0.24
  23. Jason Scott Starr · 2 shared papers, 2021 · strength 0.21
  24. Kabir Mody · 2 shared papers, 2021 · strength 0.21
  25. Douglas Dias e Silva · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.